Reactie-adaptief op Epcoritamab bij de eerste terugval: studie om de werkzaamheid van eptoritamab te evalueren bij patiënten met terugval/refractair grote B-cellymfoom (REPIFIR)
Reactie-adaptief op Epcoritamab bij de eerste terugval: een fase II, respons-adaptief, open-label, multicenter-studie om de werkzaamheid van eptoritamab te evalueren bij patiënten met terugval/refractaire grote B-cellymfoom
phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab monotherapy and, since cycle 4, they can continue with epcoritamab monotherapy until cycle 12 or change to combination therapy (epcoritamab + tafasitamab + lenalidomide) until cycle 15. Patients will be followed up to 5 years.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Epcoritamab is a full-length bispecific IgG1 antibody directed against two proteins, CD3 on the T lymphocyte and CD20 on the lymphoma cell. This antibody redirects and activates T cells, generating an immune synapse that eventually eliminates malignant cells expressing CD20.
Previous studies have demonstrated that Epcoritamab has potent antitumor activity as a monotherapy agent, with a favorable and manageable safety profile.
Since its efficacy is so favorable it is reasonable to think that it could be an excellent option for first-relapse patients. However, to date, there is no data on this therapy's usefulness as second-line treatment. Therefore we intend to evaluate the efficacy of Epcoritamab as a treatment option for patients with first-relapse LBCL.
The purpose of this study is to determine the efficacy of Epcoritamab as second line treatment for LBCL patients. On the basis of the clinical experience, it is hypothesized that Epcoritamab would provide a better complete response rate (CRR) in comparison to Platinum-based immunochemotherapy (CRR=25%), Polatuzumab-Bendamustin Rituximab (CRR=40%) and Tafasitamab-Lenalidomide (CRR=43%).
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Auxi Moreno
- Telefoonnummer: +34 683 636 850
- E-mail: amoreno@geltamo.com
Studie Contact Back-up
- Naam: Ana María Méndez
- Telefoonnummer: +34 942 203 450
- E-mail: administracion@geltamo.com
Studie Locaties
-
-
Andalusia
-
Seville, Andalusia, Spanje, 41013
- Werving
- Hospital Universitario Virgen del Rocío
-
Contact:
- Fátima de la Cruz Vicente, MD
- Telefoonnummer: +34 955 0132 61
- E-mail: fatimadelacruzv@gmail.com
-
-
Aragon
-
Zaragoza, Aragon, Spanje, 50009
- Werving
- Hospital Universitario Miguel Servet
-
Contact:
- Araceli Rubio
- Telefoonnummer: +34 976 765 690
- E-mail: arubiom@salud.aragon.es
-
-
Balearic Islands
-
Palma de Mallorca, Balearic Islands, Spanje, 07120
- Werving
- Hospital Universitario Son Espases
-
Contact:
- Antonio Gutiérrez, MD
- Telefoonnummer: 65115 +34 871 205 000
- E-mail: antoniom.gutierrez@ssib.es
-
-
Castille and León
-
Burgos, Castille and León, Spanje, 09006
- Werving
- Hospital Universitario de Burgos
-
Contact:
- Francisco Javier Díaz
- Telefoonnummer: 36071 +34 947 281 800
- E-mail: fcdiaz@saludcastillayleon.es
-
Salamanca, Castille and León, Spanje, 37007
- Werving
- Hospital Universitario de Salamanca
-
Contact:
- Alejandro Martín García-Sancho, MD
- Telefoonnummer: +34 923 291 100
- E-mail: amartingar@usal.es
-
-
Catalonia
-
Badalona, Catalonia, Spanje, 08916
- Werving
- ICO Badalona
-
Contact:
- Juan Manuel Sancho
- Telefoonnummer: +34 934 651 200
- E-mail: jsancho@iconcologia.net
-
Barcelona, Catalonia, Spanje, 08035
- Werving
- Hospital Universitari Vall d'Hebrón
-
Contact:
- Pau Abrisqueta
- Telefoonnummer: 4976 or 2697 +34 932 746 100
- E-mail: pau.abrisqueta9@gmail.com
-
-
Extremadura
-
Cáceres, Extremadura, Spanje, 10003
- Werving
- Hospital San Pedro de Alcántara
-
Contact:
- Juan Miguel Bergua
- Telefoonnummer: +34 927 621 540
- E-mail: jmberguaburg@gmail.com
-
-
Madrid
-
Madrid, Madrid, Spanje, 28041
- Werving
- Hospital Universitario 12 de Octubre
-
Contact:
- Ana Jiménez Ubieto, MD
- Telefoonnummer: +34 917 792 809
- E-mail: anitiju@hotmail.com
-
Madrid, Madrid, Spanje, 28007
- Werving
- Hospital General Universitario Gregorio Marañón
-
Contact:
- Mariana Bastos-Oreiro
- Telefoonnummer: +34 914 269 826
- E-mail: bastosmariana@yahoo.com
-
Madrid, Madrid, Spanje, 28031
- Werving
- Hospital Universitario Infanta Leonor
-
Contact:
- María Stefania Infante
- Telefoonnummer: +34 911 919 114
- E-mail: mariastefania.infante@salud.madrid.org
-
Madrid, Madrid, Spanje, 28040
- Werving
- Hospital Universitario Fundación Jiménez Díaz
-
Contact:
- Raúl Córdoba
- Telefoonnummer: +34 915 504 880
- E-mail: raul.cordoba@fjd.es
-
-
Murcia
-
El Palmar, Murcia, Spanje, 30120
- Werving
- Hospital Virgen de la Arrixaca
-
Contact:
- Almudena Cascales
- Telefoonnummer: +34 968 369 532
- E-mail: almudena.cascales@gmail.com
-
-
Málaga
-
Marbella, Málaga, Spanje, 29603
- Werving
- Hospital Universitario Costa del Sol
-
Contact:
- María Casanova
- Telefoonnummer: +34 951 976 542
- E-mail: mariacasanova@yahoo.com
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Spanje, 33011
- Werving
- Hospital Universitario Central de Asturias
-
Contact:
- Angel Ramírez
- Telefoonnummer: +34 985 652 489
- E-mail: apayer.angel@gmail.com
-
-
Tenerife
-
San Cristóbal de La Laguna, Tenerife, Spanje, 38320
- Werving
- Hospital Universitario de Canarias
-
Contact:
- María José Rodríguez
- Telefoonnummer: +34 922 678 000
- E-mail: rodriguezsalazarmariajose@gmail.com
-
-
Valencia
-
Valencia, Valencia, Spanje, 46017
- Werving
- Hospital Universitario Dr. Peset
-
Contact:
- Eva María Donato
- Telefoonnummer: +34 963 189 168
- E-mail: donato_eva@gva.es
-
Valencia, Valencia, Spanje, 46024
- Werving
- Hospital Universitario y Politécnico La Fe
-
Contact:
- Rafael Andreu
- Telefoonnummer: +34 961 244 868
- E-mail: andreu_raflap@gva.es
-
-
Vizcaya
-
Bilbao, Vizcaya, Spanje, 48013
- Werving
- Hospital Universitario de Basurto
-
Contact:
- Cristina Barrenetxea
- Telefoonnummer: +34 944 006 000
- E-mail: cristina.barrene@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Written informed consent must be obtained before any study-specific assessment is performed.
-
Age >18 years
-
Patients with Relapse/Refractory histologically confirmed LBCL, including, Diffuse Large B Cell Lymphoma (DLBCL); Primary Mediastinal Large B Cell Lymphoma (PMBCL), High-grade B-cell lymphoma (HGBCL); and grade 3B Follicular Lymphoma.
Relapsed disease is defined as complete remission to first line therapy followed by a recurrence of the disease after a minimum of 6 months of completion of first-line therapy. A biopsy at the time of relapse is recommended but not mandatory.
Refractory disease is defined as no objective response to first line therapy (biopsy not mandatory if diagnostic sample available). Four groups of patients are eligible:
- PD as best response to first line therapy.
- SD as best response after at least 4 cycles of first line therapy.
- PR as best response after at least 6 cycles of first line therapy.
- CR and disease recurrence within < 6 months from the completion of first-line therapy.
-
Patients must have received adequate first-line therapy including at a minimum: an anti-CD20 monoclonal antibody (rituximab or obinutuzumab), and CHOP (cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone) or CHOP-like chemotherapy.
-
At the investigator's discretion, the patient should not be a candidate for 1st relapse CAR-T therapy or unwilling to receive CAR-T therapy.
-
Patients must be autologous stem cell transplantation (ASCT)-ineligible: Age ≥65 and/or HTC-CI ≥3 or or unwilling to receive transplant.
-
PET positive disease.
-
Performance status according to Eastern Cooperative Oncology Group (ECOG) 0 to 2.
-
Patients meeting with the following hematology values:
- Hemoglobin ≥8 g/dl (transfusion support permitted but not within 7 days of screening lab collection)
- Absolute neutrophil count (ANC) ≥ 1/109/L (growth factor support allowed in case of bone marrow involvement).
- Absolute lymphocyte count ≥ 0.1/109/L,
- Platelet count ≥ 70/109/L (unless secondary to bone marrow involvement, OR ≥50x/109/L if documented bone marrow involvement). Platelet transfusions permitted but not within 7 days of screening lab collection.
-
Female patients of child-bearing potential must have a negative urine or serum pregnancy test at screening and agree to use highly effective methods of contraception (e.g., established use of oral, injected or implanted combined (estradiol and progesterone containing) hormonal contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS) upon enrollment according to the recommendations provided by Clinical Trial Facilitation Group (CTFG), during the treatment period and for 4 months after the last dose of study medication. Moreover, the patient must agree to ongoing pregnancy testing during the course of the study, and after study therapy has ended. This applies even if the patient practices complete and continued sexual abstinence.
Women not of childbearing potential are defined as: premenarchal; postmenopausal (greater than 50 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level greater than 40 IU per L or milli-International unit (mIU) per mL); permanently sterilized (e.g., bilateral tubal occlusion [which includes tubal ligation procedures as consistent with local regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or otherwise be incapable of pregnancy.
-
Male patients must use a reliable method of contraception (if sexually active with a female of child-bearing potential) upon enrollment according to the recommendations provided by CTFG, during the treatment period, and for 4 months following the last dose of investigational drug or agreement to remain abstinent. Agreement to refrain from donating blood or sperm during the study participation and for 4 months after the last dose of study medication.
-
Women must agree not to donate blood or oocytes during the course of the study and for 4 months after the last dose of study medication. Restrictions concerning blood donation apply as well to females who are not of childbearing potential. Men must also not donate sperm during the trial and for 4 months after receiving the last dose of study drug.
-
Females of childbearing potential must refrain from breastfeeding during the course of the study and for 4 months after the last dose of study medication.
-
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
-
Not included in other clinical trial or treated with an experimental drug.
Exclusion Criteria:
-
Patients who received more than one prior line of systemic therapy
-
Patients with detectable Central Nervous System (CNS) lymphoma
-
Significant organ function impairment:
- creatinine clearance calculated by Cockcroft-Gault ≤ 45 ml/min
- direct bilirubin level < 2 x ULN (except in patients with Gilbert's syndrome),
- alanine transaminase (ALT) and aspartate aminotransferase (AST) >3 × ULN or >5 × ULN in cases of documented liver involvement.
- clinically relevant pleural effusion,
- left ventricular ejection fraction (LVEF) ≤ 45%
-
Serious accompanying disorder leading to impaired organ function causing significant clinical problems and reduced life expectancy of less than 3 months.
-
Have a history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period
-
Known clinically significant cardiac disease, including:
- Onset of unstable angina pectoris within 6 months of signing the patient informed consent form.
- Acute myocardial infarction within 6 months of signing the patient informed consent form.
- Congestive heart failure (grade III or IV as classified by the New York Heart Association.
- Left ventricular ejection fraction ≤45%.
-
Known past or current malignancy other than inclusion diagnosis, except for: Cervical carcinoma of Stage 1B or less; Non-invasive basal cell or squamous cell skin carcinoma; Non-invasive, superficial bladder cancer; Localized low grade prostate cancer (up to Gleason score 6); DCIS of the breast; Other malignancy that has been treated with curative intent and has remained in remission for 3 years.
-
Previous ASCT.
-
Prior anti-CD3 and CD20 bispecific antibodies therapy or prior treatment with tafasitamab.
-
Presence of severe infection that is uncontrolled or requiring IV antimicrobials for management.
-
History of HIV infection or acute or chronic active hepatitis B or C infection.
- Individuals with positive HIV serology may be included if negative viral load and CD4 >200/mm3. For being included, patients should have controlled disease and been on treatment for at least 1 year
- Individuals with history of hepatitis infection with positive antibodies (anti-HB and anti-HV) might be included if negative viral load (negative hepatitis B PCR). Patients who are HBcAb positive must receive HBV prophylaxis while on treatment. Patients with positive HbsAg are excluded. Patients who are hepatitis B PCR positive will be excluded. Patients who are hepatitis C RNA positive will be excluded.
-
Females who are pregnant or breastfeeding.
-
Richter's transformation or prior chronic lymphocytic leukemia (CLL).
-
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 4 weeks prior to Cycle 1 Day 1.
-
Recent major surgery (within 4 weeks before the start of Cycle 1 Day 1) other than for diagnosis.
-
Vaccination with a live vaccine or COVID-19 vaccination within 4 weeks prior to treatment.
-
History of hypersensitivity to any of the study drugs or their ingredients or to drugs with similar structure. History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies.
-
Close affiliation with the investigator (e.g. a close relative) or persons working at the study site.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: EPCO monotherapy
Epcoritamab in monotherapy will be administred until cycle 12. |
Patients will receive 12 cycles of Epcoritamab monotherapy. |
|
Experimenteel: Combination therapy
3 cycles of Epcoritamab in monotherapy will be administred and then Epcoritamab will be administred with Tafasitamab and Lenalidomide from cycle 4 until cycle 15. |
Patients will receive 3 cycles of Epcoritamab monotherapy and then 12 cycles of Epcoritamab, Tafasitamab and Lenalidomide. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Efficacy of Epcoritamab monotherapy
Tijdsspanne: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
The efficacy of Epcoritamab monotherapy will be centrally evaluated by the best CRR at any moment since initiation. The CRR will be assessed by PET-CT according to Lugano Classification and is defined as the proportion of patients who achieve a best response of complete response (CR) at any moment since initiation of Epcoritamab first administration. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Efficacy of Epcoritamab monotherapy after 3 cycles
Tijdsspanne: At the end of cycle 3 (each cycle is 28 days)
|
The efficacy of Epcoritamab monotherapy will be centrally evaluated by the best CRR, defined as the proportion of patients who achieve a best response of CR after 3 cycles of Epcoritamab administration. |
At the end of cycle 3 (each cycle is 28 days)
|
|
Efficacy of Epcoritamab monotherapy and combination therapy by CRR
Tijdsspanne: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per CRR (locally evaluated for Epcoritamab monotherapy; local and central evaluation for combination therapy). |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
|
Evaluation of MRD
Tijdsspanne: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
The efficacy of Epcoritamab monotherapy and combination therapy will be evaluated by MRD (positive or negative) from ctDNA samples immediately before initiation of C3, C4, C7, C10, C12, C13, C15, End of Treatment (EoT) and cycles 18/24 (epcoritamab monotherapy) or cycles 21/27 (combination therapy). |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Evaluation of patients with negative MRD by PFS
Tijdsspanne: At cycle 3 visit (each cycle is 28 days).
|
The PFS of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy). |
At cycle 3 visit (each cycle is 28 days).
|
|
Safety and tolerability
Tijdsspanne: Baseline, during all the cycles day 1 visit (each cycle is 28 days) and at EoT (28 days afert las administration of Study drug).
|
The safety and tolerability of Epcoritamab monotherapy and combination therapy are evaluated as follows:
|
Baseline, during all the cycles day 1 visit (each cycle is 28 days) and at EoT (28 days afert las administration of Study drug).
|
|
Efficacy of Epcoritamab Monotherapy and Combination therapy by ORR
Tijdsspanne: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per ORR at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Efficacy of Epcoritamab Monotherapy and combination therapy by DoR
Tijdsspanne: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per DoR at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Efficacy of Epcoritamab monotherapy and combination therapy by DoCR
Tijdsspanne: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per DoCR at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Efficacy of Epcoritamab monotherapy and combination therapy by EFS
Tijdsspanne: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per Event-free survival (EFS) at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Efficacy of Epcoritamab monotherapy and combination therapy by PFS
Tijdsspanne: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per PFS at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Efficacy of Epcoritamab montherapy and combination therapy by OS
Tijdsspanne: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per OS at any time. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
|
|
Evaluation of patients with negative MRD by OS
Tijdsspanne: At cycle 3 visit (each cycle is 28 days).
|
The OS of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy). |
At cycle 3 visit (each cycle is 28 days).
|
|
Evaluation of patients with negative MRD by DoR
Tijdsspanne: At cycle 3 visit (each cycle is 28 days).
|
The DoR of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy). |
At cycle 3 visit (each cycle is 28 days).
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Response of patients stopping treatment by PFS
Tijdsspanne: At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
|
To compare the PFS of patients stopping therapy after 1 year of treatment (CR by PET-CT and negative MRD) with the groups of patients who continue monotherapy or receive combination. |
At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
|
|
Correlation between biomarkers and study treatment by ORR
Tijdsspanne: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Correlation between biomarkers and study treatment efficacy determined by ORR. |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by DoR
Tijdsspanne: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days).
|
Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by DoR in patients reintroducing the study treatment with a MRD positive result. |
After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days).
|
|
MRD negativity
Tijdsspanne: through study completion, an average of 5 years
|
Median duration of molecular response (MRD negativity). |
through study completion, an average of 5 years
|
|
Correlation between tumor volume and efficacy
Tijdsspanne: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
Correlation between Total Metabolic Tumor Volume (centrally evaluated) and study treatment efficacy determined by PFS and OS. |
Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
|
|
ctDNA levels
Tijdsspanne: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Descriptive analysis of dynamic changes in ctDNA levels |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Correlation between lymphocyte subsets and efficacy
Tijdsspanne: Through study completion, an average of 5 years.
|
Correlation between lymphocyte subsets and study treatment efficacy determined by ORR, CRR, DoR, PFS and OS and safety determined by type, frequency, and severity of adverse events. |
Through study completion, an average of 5 years.
|
|
Response of patients stopping treatment
Tijdsspanne: At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
|
To compare the DoR of patients stopping therapy after 1 year of treatment (CR by PET-CT and negative MRD) with the groups of patients who continue monotherapy or receive combination. |
At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
|
|
Correlation between biomarkers and study treatment efficacy by CRR
Tijdsspanne: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Correlation between biomarkers and study treatment efficacy determined by CRR. |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Correlation between biomarkers and study treatment efficacy DoR
Tijdsspanne: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Correlation between biomarkers and study treatment efficacy determined by DoR, PFS and OS. |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Correlation between biomarkers and study treatment efficacy by PFS
Tijdsspanne: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Correlation between biomarkers and study treatment efficacy determined by PFS. |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Correlation between biomarkers and study treatment efficacy by OS
Tijdsspanne: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
Correlation between biomarkers and study treatment efficacy determined by OS. |
Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
|
|
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by PFS
Tijdsspanne: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)
|
Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by PFS in patients reintroducing the study treatment with a MRD positive result. |
After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)
|
|
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by OS
Tijdsspanne: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)
|
Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by OS in patients reintroducing the study treatment with a MRD positive result. |
After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Mariana Bastos-Oreiro, Hospital General Universitario Gregorio Marañon
- Hoofdonderzoeker: Pau Abrisqueta, Hospital Universitari Vall d'Hebrón
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata
- Ziekte attributen
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Lymfoom, non-Hodgkin
- Lymfoom, B-cel
- Pathologische aandoeningen, tekenen en symptomen
- Hemische en lymfatische ziekten
- Herhaling
- Lymfoom
- Lymfoom, grote B-cel, diffuus
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Carbonzuren
- Piperidines
- Phtalimiden
- Phtaliczuren
- Zuren, carbocyclisch
- Piperidones
- Isoindoles
- Lenalidomide
- tafasitamab
Andere studie-ID-nummers
- REPIFIR-AGR-GEL-23
- 2024-514440-86-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Data obtained through this study may be provided to qualified researchers with academic interest in hematology diseases. All individual data collected during the trial will be available. Data shared will be coded, with no PHI included. Study protocol, statistical analysis plan, informed consent form and clinical study report will be also available. Information will be available beginning 6 months after final publication with no end date established. Approval of the request and execution of all applicable agreements are prerequisites to the sharing of data with the requesting party. Data requests can be submitted starting 6 months after article publication. Access to trial IPD can be requested by qualified researchers and will be provided following review and approval of a research and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact to GELTAMO though the web page: https://www.geltamo.com/contacto
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .